Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121014 | 0.84 | IDO1 (0.42) | IDO1AGXTKDM5AKDM4CKDM5B | |
| Ammonia Solution, Strong SCHEMBL28443748 | 0.82 | IDO1 (0.41) | IDO1AGXTKDM5AKDM4CKDM5B | |
| SCHEMBL3083666 | 0.80 | IDO1 (0.42) | IDO1AGXTKDM5AKDM4CKDM5B | |
| SCHEMBL16706451 | 0.78 | IDO1 (0.38) | IDO1AGXTKDM5AKDM4CKDM5B | |
| SCHEMBL13172532 | 0.77 | IDO1 (0.37) | IDO1AGXTKDM5AKDM4CKDM5B | |
| SCHEMBL12936610 | 0.76 | IDO1 (0.39) | IDO1AGXTKDM5AKDM4CKDM5B | |
| SCHEMBL18213791 | 0.76 | RORC (0.40) | IDO1AGXTKDM5AKDM4CKDM5B | |
| SCHEMBL18590775 | 0.74 | TAAR1 (0.45) | ACHETAAR1P2RX7 | |
| SCHEMBL13932536 | 0.74 | AMY1A (0.42) | IDO1AGXTKDM4CACHETAAR1 | |
| SCHEMBL13172290 | 0.73 | MAPK14 (0.40) | IDO1AGXTKDM5AKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731493-B1 | BENZENE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | CHISSO CORP (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| EP-1731493-A1 | BENZENE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | CHISSO CORPORATION (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | IDO1 2102/4885AGXT 3466/4885KDM5A 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.